Tricuspid regurgitation screening: Difference between revisions
Line 23: | Line 23: | ||
OR | OR | ||
* Genetic conditions like which might lead to tricuspid valve regurgitation include: | * Genetic conditions like which might lead to tricuspid valve regurgitation include:<ref name="pmid19031473">{{cite journal| author=Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH| title=Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. | journal=Ultrasound Obstet Gynecol | year= 2009 | volume= 33 | issue= 1 | pages= 18-22 | pmid=19031473 | doi=10.1002/uog.6264 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19031473 }}</ref> | ||
** Trisomy 21 | ** Trisomy 21 | ||
** Trisomy 18 | ** Trisomy 18 |
Revision as of 11:09, 13 April 2020
Tricuspid Regurgitation Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Tricuspid regurgitation screening On the Web |
American Roentgen Ray Society Images of Tricuspid regurgitation screening |
Risk calculators and risk factors for Tricuspid regurgitation screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is insufficient evidence to recommend routine screening for tricuspid valve regurgitation. But there are some genetic conditions which might lead to tricuspid valve regurgitation and can be screened.
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
- Genetic conditions like which might lead to tricuspid valve regurgitation include:[1]
- Trisomy 21
- Trisomy 18
- Trisomy 13
- Turner syndrome
- Screening can be done by using the following in these patients, assessment of tricuspid blood flow along with the following:
- Fetal nuchal translucency (NT) thickness
- Fetal heart rate (FHR)
- Serum free beta-human chorionic gonadotropin (beta-hCG)
- Pregnancy-associated plasma protein A (PAPP-A)
- [Condition 1]
- [Condition 2]
- [Condition 3]
References
- ↑ Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH (2009). "Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation". Ultrasound Obstet Gynecol. 33 (1): 18–22. doi:10.1002/uog.6264. PMID 19031473.